Document Detail


The ryanodine receptor in cardiac physiology and disease.
MedLine Citation:
PMID:  20933197     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
According to the American Heart Association it is estimated that the United States will spend close to $39 billion in 2010 to treat over five million Americans suffering from heart failure. Patients with heart failure suffer from dyspnea and decreased exercised tolerance and are at increased risk for fatal ventricular arrhythmias. Food and Drug Administration -approved pharmacologic therapies for heart failure include diuretics, inhibitors of the renin-angiotensin system, and β-adrenergic receptor antagonists. Over the past 20 years advances in the field of ryanodine receptor (RyR2)/calcium release channel research have greatly advanced our understanding of cardiac physiology and the pathogenesis of heart failure and arrhythmias. Here we review the key observations, controversies, and discoveries that have led to the development of novel compounds targeting the RyR2/calcium release channel for treating heart failure and for preventing lethal arrhythmias.
Authors:
Alexander Kushnir; Andrew R Marks
Related Documents :
12556677 - Hyperthyroidism: a "curable" cause of congestive heart failure--three case reports and ...
18158477 - Systolic heart failure: chronic and acute syndromes.
19372677 - Sunitinib malate, a receptor tyrosine kinase inhibitor, is effective in the treatment o...
25464237 - Remote ischemic preconditioning reduces contrast-induced acute kidney injury in patient...
7797747 - Dispersion of qt interval in patients with and without susceptibility to ventricular ta...
8027957 - Cognitive-behavioural interventions in cardiac rehabilitation.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Advances in pharmacology (San Diego, Calif.)     Volume:  59     ISSN:  1557-8925     ISO Abbreviation:  Adv. Pharmacol.     Publication Date:  2010  
Date Detail:
Created Date:  2010-10-11     Completed Date:  2010-11-04     Revised Date:  2014-09-18    
Medline Journal Info:
Nlm Unique ID:  9015397     Medline TA:  Adv Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1-30     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Atrial Fibrillation / metabolism*,  physiopathology,  therapy
Calcium-Calmodulin-Dependent Protein Kinase Type 2 / metabolism
Cardiovascular Agents / chemistry,  metabolism,  therapeutic use
Cyclic AMP-Dependent Protein Kinases / metabolism
Drug Design
Heart Conduction System* / physiology,  physiopathology
Heart Failure / metabolism*,  physiopathology,  therapy
Humans
Infant, Newborn
Myocardial Contraction* / physiology
Phosphorylation
Receptors, Adrenergic, beta / metabolism,  physiology
Ryanodine Receptor Calcium Release Channel / chemistry,  drug effects,  physiology*
Sudden Infant Death / genetics,  prevention & control
Tachycardia, Ventricular / metabolism*,  physiopathology,  therapy
Tacrolimus Binding Proteins / metabolism
Grant Support
ID/Acronym/Agency:
HL056180/HL/NHLBI NIH HHS; HL061503/HL/NHLBI NIH HHS; P01 HL067849/HL/NHLBI NIH HHS; P01 HL067849-10/HL/NHLBI NIH HHS; R01 HL056180/HL/NHLBI NIH HHS; R01 HL056180-15/HL/NHLBI NIH HHS; R01 HL061503/HL/NHLBI NIH HHS; R01 HL061503-13/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Cardiovascular Agents; 0/Receptors, Adrenergic, beta; 0/Ryanodine Receptor Calcium Release Channel; EC 2.7.11.11/Cyclic AMP-Dependent Protein Kinases; EC 2.7.11.17/Calcium-Calmodulin-Dependent Protein Kinase Type 2; EC 5.2.1.-/Tacrolimus Binding Proteins
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Foreword.
Next Document:  Neuregulin-1/ErbB Signaling and Chronic Heart Failure.